Heart Surgeons Want CMS To Rethink Indications For LVADs, Recognize Transplant “Bridge-To-Decision” Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
The current two-indication system for approving and covering left-ventricular assist devices does not reflect the reality of heart failure patients receiving these devices, according to transplant surgeons.
You may also be interested in...
HeartWare Touts Early Success In U.S. Launch Of HVAD
HeartWare sold 134 HVAD ventricular assist systems in the U.S. following FDA approval in November and continues to rapidly add more centers to its customer base.
Reimbursement In Brief
CMS opens national coverage analysis on VADs, proposes regulatory reform and announces new ESRD initiative. More reimbursement news.
Medicare Panel Laments Holes In Ventricular Assist Device Evidence Base
CMS does not currently have a national coverage determination process open on ventricular assist devices for heart failure, though the agency may open a new one, an agency official said.